383 related articles for article (PubMed ID: 34952597)
21. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
22. High efficiency closed-system gene transfer using automated spinoculation.
Remley VA; Jin J; Sarkar S; Moses L; Prochazkova M; Cai Y; Shao L; Liu H; Fuksenko T; Jin P; Stroncek DF; Highfill SL
J Transl Med; 2021 Nov; 19(1):474. PubMed ID: 34819105
[TBL] [Abstract][Full Text] [Related]
23. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
[TBL] [Abstract][Full Text] [Related]
24. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry.
Maryamchik E; Gallagher KME; Preffer FI; Kadauke S; Maus MV
Cytometry B Clin Cytom; 2020 Jul; 98(4):299-327. PubMed ID: 32352629
[TBL] [Abstract][Full Text] [Related]
25. The challenge of standardizing CAR-T cell monitoring: A comparison of two flow-cytometry methods and correlation with qPCR technique.
Valdivieso-Shephard JL; Matas-Pérez E; García-Bujalance S; Mirones-Aguilar I; González-Martínez B; Pérez-Martínez A; López-Granados E; Martínez-Feito A; Sánchez-Zapardiel E
Cytometry A; 2024 May; 105(5):368-375. PubMed ID: 38327134
[TBL] [Abstract][Full Text] [Related]
26. Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4.
Alsalloum A; Shevchenko J; Fisher M; Philippova J; Perik-Zavodskii R; Perik-Zavodskaia O; Alrhmoun S; Lopatnikova J; Vasily K; Volynets M; Zavjalov E; Solovjeva O; Akahori Y; Shiku H; Silkov A; Sennikov S
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894816
[TBL] [Abstract][Full Text] [Related]
27. Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel.
Peinelt A; Bremm M; Kreyenberg H; Cappel C; Banisharif-Dehkordi J; Erben S; Rettinger E; Jarisch A; Meisel R; Schlegel PG; Beck O; Bug G; Klusmann JH; Klingebiel T; Huenecke S; Bader P
Front Immunol; 2022; 13():830773. PubMed ID: 35309367
[TBL] [Abstract][Full Text] [Related]
28. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
29. Assessment and comparison of viability assays for cellular products.
Cai Y; Prochazkova M; Kim YS; Jiang C; Ma J; Moses L; Martin K; Pham V; Zhang N; Highfill SL; Somerville RP; Stroncek DF; Jin P
Cytotherapy; 2024 Feb; 26(2):201-209. PubMed ID: 38085197
[TBL] [Abstract][Full Text] [Related]
30. Highly efficient gene transfer using a retroviral vector into murine T cells for preclinical chimeric antigen receptor-expressing T cell therapy.
Kusabuka H; Fujiwara K; Tokunaga Y; Hirobe S; Nakagawa S; Okada N
Biochem Biophys Res Commun; 2016 Apr; 473(1):73-79. PubMed ID: 26993168
[TBL] [Abstract][Full Text] [Related]
31. A TCR-based Chimeric Antigen Receptor.
Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
[TBL] [Abstract][Full Text] [Related]
32. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
33. Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies.
Song HW; Somerville RP; Stroncek DF; Highfill SL
Int Rev Immunol; 2022; 41(6):638-648. PubMed ID: 35486592
[TBL] [Abstract][Full Text] [Related]
34. Detection of CAR-T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories.
Johansson U; Gallagher K; Burgoyne V; Maus MV; Casey KS; Brini GG; Frigault MJ; Yam JY; Chavda N; Besley C; Lugthart S
Cytometry B Clin Cytom; 2021 Nov; 100(6):622-631. PubMed ID: 33915021
[TBL] [Abstract][Full Text] [Related]
35. TCR-independent Activation in Presence of a Src-family Kinase Inhibitor Improves CAR-T Cell Product Attributes.
Lamture G; Baer A; Fischer JW; Colon-Moran W; Bhattarai N
J Immunother; 2022 Apr; 45(3):139-149. PubMed ID: 34802014
[TBL] [Abstract][Full Text] [Related]
36. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
37. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
Shafer P; Kelly LM; Hoyos V
Front Immunol; 2022; 13():835762. PubMed ID: 35309357
[TBL] [Abstract][Full Text] [Related]
38. Flow cytometry detection and quantification of CAR T cells into solid tumors.
Tokarew NJA; Gosálvez JS; Nottebrock A; Briukhovestka D; Endres S; Cadilha BL; Kobold S
Methods Cell Biol; 2022; 167():99-122. PubMed ID: 35153001
[TBL] [Abstract][Full Text] [Related]
39. Monitoring CAR T-cells using flow cytometry.
Demaret J; Varlet P; Trauet J; Beauvais D; Grossemy A; Hégo F; Yakoub-Agha I; Labalette M
Cytometry B Clin Cytom; 2021 Mar; 100(2):218-224. PubMed ID: 32841511
[TBL] [Abstract][Full Text] [Related]
40. Manufacturing chimeric antigen receptor T cells: issues and challenges.
Roddie C; O'Reilly M; Dias Alves Pinto J; Vispute K; Lowdell M
Cytotherapy; 2019 Mar; 21(3):327-340. PubMed ID: 30685216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
